Cargando…

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia

Despite several new therapeutic options for acute myeloid leukemia (AML), disease relapse remains a significant challenge. We have previously demonstrated that augmenting ceramides can counter various drug‐resistance mechanisms, leading to enhanced cell death in cancer cells and extended survival in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khokhlatchev, Andrei V., Sharma, Arati, Deering, Tye G., Shaw, Jeremy J. P., Costa‐Pinheiro, Pedro, Golla, Upendarrao, Annageldiyev, Charyguly, Cabot, Myles C., Conaway, Mark R., Tan, Su‐Fern, Ung, Johnson, Feith, David J., Loughran, Thomas P., Claxton, David F., Fox, Todd E., Kester, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544744/ https://www.ncbi.nlm.nih.gov/pubmed/36106439 http://dx.doi.org/10.1096/fj.202200765R

Ejemplares similares

Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma
por: Sakae, Harumi, et al.
Publicado: (2023)

Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia
por: Fisher-Wellman, Kelsey H., et al.
Publicado: (2023)

DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia
por: Golla, Upendarrao, et al.
Publicado: (2021)

The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020)

C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia
por: Ryland, Lindsay K., et al.
Publicado: (2013)

Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice
por: Li, Guangfu, et al.
Publicado: (2018)

The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia
por: Annageldiyev, Charyguly, et al.
Publicado: (2020)

STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia
por: Doshi, Ushma A, et al.
Publicado: (2017)

Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound
por: Thim, E. Andrew, et al.
Publicado: (2023)

Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes
por: Paudel, B. Bishal, et al.
Publicado: (2023)

Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation
por: Barth, Brian M, et al.
Publicado: (2014)

Cytarabine/venetoclax: Recurrent Corynebacterium bacteraemia: case report
Publicado: (2022)

Downregulation of CD73 associates with T cell exhaustion in AML patients
por: Kong, Yaxian, et al.
Publicado: (2019)

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Acid ceramidase is upregulated in AML and represents a novel therapeutic target
por: Tan, Su-Fern, et al.
Publicado: (2016)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Evaluation of Antioxidant and DNA Damage Protection Activity of the Hydroalcoholic Extract of Desmostachya bipinnata L. Stapf
por: Golla, Upendarrao, et al.
Publicado: (2014)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

Combined Transcriptomics and Chemical-Genetics Reveal Molecular Mode of Action of Valproic acid, an Anticancer Molecule using Budding Yeast Model
por: Golla, Upendarrao, et al.
Publicado: (2016)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells
por: Qian, Fenghua, et al.
Publicado: (2023)

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
por: Wei, Andrew H., et al.
Publicado: (2019)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
por: Zhang, Guangji, et al.
Publicado: (2022)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
por: Asada, Noboru, et al.
Publicado: (2023)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases
por: Kale, Vijay Pralhad, et al.
Publicado: (2023)

Depletion of Cellular Iron by Curcumin Leads to Alteration in Histone Acetylation and Degradation of Sml1p in Saccharomyces cerevisiae
por: Azad, Gajendra Kumar, et al.
Publicado: (2013)

Correction: Depletion of Cellular Iron by Curcumin Leads to Alteration in Histone Acetylation and Degradation of Sml1p in Saccharomyces cerevisiae
por: Azad, Gajendra Kumar, et al.
Publicado: (2013)

A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)
por: Golla, Upendarrao, et al.
Publicado: (2017)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
por: Song, Bao‐Quan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_14e4ccdmop9e7se2mrskne7dh5